Hair greying and follicle regeneration: which rejuvenation claims have made it beyond mice?

Reader questions answered

Why does hair turn grey with age?

A growing hair gets its colour from melanin supplied by pigment-producing cells called melanocytes. When a follicle supplies less pigment to a new hair shaft, that hair can grow out grey or white. Ageing can involve loss or dysfunction of melanocytes and the stem-cell reservoir that helps replenish them. Inherited factors and other influences affect timing.

The biology is more complicated than one switch turning off. An NIH summary of mouse research describes pigment-lineage cells moving between follicle compartments and changing state. The relative contributions of impaired movement, cell depletion and other mechanisms in any individual human follicle remain unresolved.

A review of premature greying also discusses associations with deficiencies. An association does not mean everyone with grey hair has a deficiency, or that supplements reverse ordinary age-related greying.

What do melanocyte stem cells do?

Melanocyte stem cells help replenish the melanocytes needed to pigment hair across successive growth cycles. Their location and state can matter as a new hair develops.

In genetically labelled mice, researchers tracked cells moving between follicle compartments and returning toward a stem-cell state. They compared hair-cycle stages and younger and older follicles, using microscopy and molecular analysis to observe cell location and state. More cells became trapped away from a region called the hair germ as follicles aged, according to the NIH account.

Sample sizes were not verified, and the original paper could not be fully inspected. This was a study of biology, not a test of how much colour a treatment restored. How closely the detailed mouse movement model applies to ageing human scalp follicles remains uncertain.

What have animal experiments shown—and what haven't they?

Mouse lineage-tracing work supports the idea that pigment-cell identity and position are dynamic, and that age-related changes in this system may contribute to greying. It does not establish that a serum can move trapped cells, make them functional or restore colour in people.

A separate 2025 mouse study examined DNA damage and competing pigment stem-cell fates. Irradiation depleted pigment stem cells and caused greying; certain experimental interventions partly blocked that greying. Under carcinogenic conditions, damaged cells could instead be diverted toward melanoma. Comparisons included non-irradiated or differently treated and genetically modified mice. Sample sizes varied by experiment and were not extracted from the available evidence.

Preventing experimentally induced damage is not the same as reversing established, ordinary age-related greying. Irradiation, carcinogens and genetic manipulation were research tools, not cosmetic treatments. The cancer-related findings are a reason to examine interventions carefully, not evidence that a particular commercial hair product causes melanoma.

Are there reliable human trials of pigment restoration?

Human research has moved beyond animal experiments, but the accessible evidence does not establish a reliable regimen. A randomized, double-blind, placebo-controlled report, published online in October 2026, describes 173 completers aged 28–65 who began with 5–25% grey hair.

The study had four groups: both active products, supplement with placebo serum, serum with placebo supplement, and double placebo. This design can, in principle, help distinguish the combined regimen from its components and from placebo effects.

But the accessible excerpt does not provide verifiable numerical results. The full article could not be accessed to check the number originally randomized, withdrawals, primary endpoint, adverse-event tables or funding. Nor can this review establish whether an observed appearance change represented new melanin production in individual follicles, how long any effect lasted after stopping, or whether independent researchers replicated it. A check for corrections and related notices was attempted, but restricted or non-rendering pages prevented a conclusive status check.

The trial is a material development, not something to dismiss because it involves products. Equally, its design alone cannot tell a reader how well the regimen works or how safe it is. More complete, accessible evidence is required.

How is greying science different from hair-loss treatment or follicle regeneration?

Pigment restoration asks whether a follicle can put melanin back into newly growing hair. Hair-loss treatment asks whether coverage can be maintained or improved. Those are different outcomes: a treatment can address thinning without reversing grey hair.

The premature-greying review distinguishes pigmentation from hair-density treatment. Minoxidil and finasteride are discussed in the hair-loss context, not as established ways to restore grey hair's colour. Improving coverage also does not, by itself, demonstrate that an entirely new follicle has regenerated or that its pigment stem cells have recovered.

Formulation matters for safety. The FDA warned about compounded topical finasteride, including local and systemic risks and inadvertent transfer to others. Adverse-event reports alone do not establish how often a problem occurs or prove causation. If thinning is a separate concern, a clinician can help identify the cause and discuss appropriate options without treating a density outcome as proof of repigmentation.

Which commercial claims are premature?

Claims that a product broadly reverses greying or rejuvenates follicle stem cells go beyond what the accessible evidence establishes. The controlled supplement-and-serum study deserves more attention than a testimonial alone, but its accessible excerpt does not allow the numerical outcomes, adverse events or disclosures to be assessed. Further sourcing is needed to verify specific retail marketing claims.

A change in grey-hair appearance is not automatically proof that a follicle has resumed durable melanin production. Nor can findings from people with 5–25% grey hair at baseline simply be assumed to apply to people with much more grey hair, or to products with different formulations. A patent, a plausible ingredient mechanism or a before-and-after photograph cannot settle those questions either.

The distinction is between category science—research into how pigment cells behave—and retail proof that a particular product produces a meaningful, durable benefit in people. The former can suggest what to study; it does not certify the latter. No product price was verified in the dossier, so a cost comparison requires further sourcing.

What safety and delivery barriers remain?

A candidate treatment would need to reach the relevant follicle cells at an effective dose, do something useful over hair cycles and avoid unacceptable local or systemic effects. Those are separate hurdles. Applying an ingredient to the scalp does not prove that it reaches the intended cells or alters them in the desired way.

The 2025 mouse work on damaged pigment cells illustrates why cell-survival and growth pathways warrant particular caution. It does not predict that a specific consumer product will cause cancer. Human studies would need to investigate irritation and other harms, exposure beyond the scalp, durability and whether adverse effects resolve after stopping. Long-term safety and an appropriate dose are not established.

Supplements present another question: taking one without a demonstrated need can introduce unnecessary exposure, and an association with deficiency does not establish benefit for ordinary ageing. US cosmetic, supplement and drug categories have different regulatory requirements; a product being sold is not proof that it has drug approval or proven efficacy. Rules elsewhere need country-specific checking.

What realistic options can readers consider today?

Leaving hair grey, cutting or styling it, and using cosmetic colour are practical choices; none requires a claim that follicle biology has been rejuvenated. Hair dye changes appearance rather than proving restoration of the follicle's pigment machinery.

Dye is not risk-free. The FDA advises following product instructions and performing the specified skin test before each use. A negative test does not guarantee that a reaction will not occur. Seek care for a significant reaction, and remember that the FDA's guidance concerns the US rather than automatically describing rules elsewhere.

If greying is unusually early or occurs alongside other symptoms, consider discussing whether assessment for an underlying condition or deficiency is appropriate. Correcting a deficiency can matter for health, but it does not guarantee colour will return. If the concern is thinning as well as colour, ask about those goals separately; a diagnosis-specific hair-loss plan is not the same thing as a grey-hair reversal plan.

Sources and conflicts

This article draws on the NIH account of mouse lineage tracing, the 2025 mouse study, the premature-greying review, the accessible 2026 trial record, and FDA guidance on hair dyes and compounded topical finasteride.

The review predates the human trial report, so it does not incorporate that newer evidence. The NIH summary notes funding including NIH and US Department of Defense grants. Funding for the 2025 mouse experiments and the human product trial could not be fully verified here. The source review was bounded, not systematic; a link to a reported claim is not independent verification of it.